Press

Acarix presents at Redeye: Commercialization Seminar

06 Mar

On March 7 at 10.30 CET Helen Ljungdahl Round, CEO of Acarix, presents the latest developments in the company at Redeye.

The presentation is live broadcasted and can be followed at https://www.redeye.se/events/868833/redeye-theme-commercialisation where the replay and the presentations will be available afterwards.

For more information contact:
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email [email protected] 
Christian Lindholm, CFO, phone +46 705 118333, email [email protected]

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, [email protected]) is Certified Advisor of Acarix. For more information, please visit www.acarix.com. 

Attachments
Acarix presents at Redeye: Commercialization Seminar

Tags:
,
Newer Study published in Heart strengthens diagnostic value of Acarix CADScor System
Back to list
Older Acarix presents at Redeye: Commercialization Seminar

Related Posts